In vitro studies using ovarian cancer cell lines A2780 and SKOV3 reveal that SLT reduces cell viability by activating a ROS-mediated p53 pathway, resulting in G1 cell cycle arrest, enhanced apoptosis, and inhibition of cell migration and invasion. Here, TP53 is linked to ovarian carcinoma.